MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 534814 | Name: Eprazinone dihydrochloride
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Eprazinone HCl is a bioactive chemical. Eprazinone has been variously described as having mucolytic or expectorant properties as well as a direct relaxant action on bronchial smooth muscle and it suppress the excitation of cough center to stop coughing.

Chemical Structure

Eprazinone dihydrochloride
Eprazinone dihydrochloride
CAS#10402-53-6 (2HCl)

Theoretical Analysis

MedKoo Cat#: 534814

Name: Eprazinone dihydrochloride

CAS#: 10402-53-6 (2HCl)

Chemical Formula: C24H34Cl2N2O2

Exact Mass: 0.0000

Molecular Weight: 453.45

Elemental Analysis: C, 63.57; H, 7.56; Cl, 15.64; N, 6.18; O, 7.06

Price and Availability

Size Price Availability Quantity
5g USD 250.00 2 Weeks
25g USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
10402-53-6 (2HCl) 10402-90-1 (free base)
Synonym
Eprazinone 2HCl; Eprazinone Hydrochloride; Eprazinone Dihydrochloride; NSC 317935; NSC317935; NSC-317935
IUPAC/Chemical Name
3-(4-(2-ethoxy-2-phenylethyl)piperazin-1-yl)-2-methyl-1-phenylpropan-1-one dihydrochloride
InChi Key
BPMQVOKMMQFZGV-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H32N2O2.2ClH/c1-3-28-23(21-10-6-4-7-11-21)19-26-16-14-25(15-17-26)18-20(2)24(27)22-12-8-5-9-13-22;;/h4-13,20,23H,3,14-19H2,1-2H3;2*1H
SMILES Code
O=C(C(CN1CCN(CC1)CC(C2=CC=CC=C2)OCC)C)C3=CC=CC=C3.Cl[H].Cl[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 453.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Thrall RS, Cloutier MM, Guernsey L, Swayne E, Gionfriddo M. Eprazinone alters lung lavage lipid levels and transtracheal ion transport. Exp Lung Res. 1992 May-Jun;18(3):409-20. doi: 10.3109/01902149209031693. PMID: 1628570. 2: Krautscheid Y, Senning CJ, Sartori SB, Singewald N, Schuster D, Stuppner H. Pharmacophore modeling, virtual screening, and in vitro testing reveal haloperidol, eprazinone, and fenbutrazate as neurokinin receptors ligands. J Chem Inf Model. 2014 Jun 23;54(6):1747-57. doi: 10.1021/ci500106z. Epub 2014 Jun 12. PMID: 24849814. 3: Yamamura T, Ohta T, Taira T, Ogawa Y, Sakai Y, Moribe K, Yamamoto K. Effects of automated external lubrication on tablet properties and the stability of eprazinone hydrochloride. Int J Pharm. 2009 Mar 31;370(1-2):1-7. doi: 10.1016/j.ijpharm.2008.11.007. Epub 2008 Nov 18. PMID: 19059327. 4: Tanabe K, Tsuboi H, Maejima H, Arai S, Katsuoka K. Non-pigmented fixed drug eruption induced by eprazinone hydrochloride. Dermatol Online J. 2005 Dec 1;11(3):25. PMID: 16409921. 5: Faber M, Maucher OM, Stengel R, Goerttler E. Eprazinonexanthem mit subkornealer Pustelbildung [Eprazinone exanthema with subcorneal pustulosis]. Hautarzt. 1984 Apr;35(4):200-3. German. PMID: 6724909. 6: Spitzer W. Die Wirksamkeit von Eprazinon-dihydrochlorid (Eftapan) in der Doppelblind-Studie [The efficacy of eprazinone dihydrochloride (Eftapan) in double-blind studies]. Fortschr Med. 1980 Jun 12;98(22):(871-4). German. PMID: 6997154. 7: Constantin M, Pognat JF, Streichenberger G. Absorption, distribution and excretion of eprazinone in animals. Arzneimittelforschung. 1974 Nov;24(11):1793-8. PMID: 4480052. 8: Toffel-Nadolny P, Gielsdorf W. Zum Metabolismus von Eprazinon [On the metabolism of eprazinone (author's transl)]. Arzneimittelforschung. 1981;31(4):719-22. German. PMID: 7195719. 9: Haber P, Burghuber O, Wolf C. Der bronchospasmolytische Effekt von Eprazinon [The bronchospasmolytic effect of eprazinone]. Prax Klin Pneumol. 1985 Feb;39(2):54-8. German. PMID: 3983078. 10: Takanashi S, Hinoara Y, Toira Y, Kamiyama H, Suzuki H. [Metabolic fate of Eprazinone hydrochloride. I. Absorption, distribution, and excretion of Eprazinone hydrochloride in vivo (author's transl)]. Yakugaku Zasshi. 1975 Aug;95(8):1002-9. Japanese. doi: 10.1248/yakushi1947.95.8_1002. PMID: 1237598. 11: Merigot P, Garnier R, Efthymiou ML. Les convulsions avec trois antitussifs dérivés substitués de la pipérazine (zipéprol, éprazinone, éprozinol) [Convulsions with 3 antitussive substituted derivatives of piperazine (zipeprol, eprazinone, eprozinol)]. Ann Pediatr (Paris). 1985 Jun;32(6):504-6, 511. French. PMID: 4026148. 12: Degand P, van der Loo D, Biserte G. Traitement de l'hypersécrétion bronchique. Mise en évidence d'interactions mucines polyanioniques-éprazinone [Treatment of bronchial hypersecretion. Demonstration of polyanionic mucins- eprazinone interactions]. Poumon Coeur. 1976;32(4):185-8. French. PMID: 981126. 13: Kimura K, Ogiya S, Hinoara Y, Takanashi S. [Metabolic fate of Eprazinone hydrochloride. III. Oxidative N-C cleavage of Eprazinone hydrochloride by a rat liver enzyme (author's transl)]. Yakugaku Zasshi. 1975 Aug;95(8):901-5. Japanese. doi: 10.1248/yakushi1947.95.8_901. PMID: 1237604. 14: Rudkowski Z, Latos T. Behandlung von Bronchitiden bei Kindern mit Eprazinon [Therapy of bronchitis in childhood with Eprazinone (author's transl)]. Padiatr Padol. 1980;15(4):351-64. German. PMID: 7007990. 15: Takanashi S, Toira Y, Suzuki H, Ogiya S, Sakuma A. [Metabolic fate of Eprazinone hydrochloride. II. Metabolites of Eprazinone hydrochloride in vivo (author's transl)]. Yakugaku Zasshi. 1975 Aug;95(8):897-900. Japanese. doi: 10.1248/yakushi1947.95.8_897. PMID: 1237603. 16: Matthys H. Prüfung von Eprazinone, einer neuen Substanz mit antiobstruktiver Wirkung auf die Atemwege [Testing of Eprazinone, a new drug with antiobstructive effect on the respiratory tract]. Med Welt. 1975 Mar 14;26(11):520-1. German. PMID: 1091804. 17: Bury T, Corhay JL, Radermecker MF. Du bon usage des mucocinétiques [Kinetics of mucus]. Rev Med Liege. 1990 Jan 1;45(1):29-33. French. PMID: 2305139. 18: Kasé Y, Yakushiji T, Seo H, Sakata M, Kito G. [Pharmacological studies on expectorants (author's transl)]. Nihon Yakurigaku Zasshi. 1977 Jul;73(5):605-24. Japanese. doi: 10.1254/fpj.73.605. PMID: 924268. 19: Opl G. Klinische Anwendung von Eprazinon-dihydrochlorid (Eftapan) [Clinical use of eprazinon-dihydrochloride (Eftapan)]. Fortschr Med. 1978 Jan 12;96(2):79-80. German. PMID: 620966. 20: Bauer C. Prüfung von Eftapan im Vergleich zu Bromhexin bei Kindern in ambulanter Behandlung [Proof of eftapan in comparison to bromhexine in children in ambulatory care]. Fortschr Med. 1981 Nov 12;99(42):1769-72. German. PMID: 7030893.